While multiple studies have confirmed that TAVR and surgery are associated with comparable outcomes, it is important to take an individualized approach to all treatment decisions.

The new surgical valve from Foldax was designed to limit calcification and make it so patients do not require long-term anticoagulant therapy following treatment. 

Medtronic’s TAVR technology received a significant amount of attention during the very first New York Valves conference in New York City. Research focused on patients with small annuli as well as how five-year outcomes compare to surgery. 

Researchers explored five-year data from more than 1,300 TAVR patients treated with a balloon-expandable Sapien 3 valve, sharing their findings at New York Valves 2024: The Structural Heart Summit.

Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Osteosarcopenia, an age-related condition associated with deterioration in the muscles and bones, nearly triples a patient’s risk of dying within one year of undergoing TAVR. 

Researchers examined data from eight different studies, noting that transcaval TAVR appears to be a "viable alternative" when transfemoral access is not an option. The procedure was linked to an overall success rate of 98.5%.